AbbVie Inc (ABBV)vsBioLineRx Ltd (BLRX)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
BLRX
BioLineRx Ltd
$3.23
-3.87%
HEALTHCARE · Cap: $14.76M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4480570% more annual revenue ($62.82B vs $1.40M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. BLRX appears more attractively valued with a PEG of 0.20. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
BLRX
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for BLRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 87.1% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -53.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : BLRX
The strongest argument for BLRX centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 87.1% demonstrates continued momentum. PEG of 0.20 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : BLRX
The primary concerns for BLRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while BLRX is a hypergrowth play — different risk/reward profiles.
BLRX carries more volatility with a beta of 0.62 — expect wider price swings.
BLRX is growing revenue faster at 87.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 43/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
BioLineRx Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company is headquartered in Hevel Modi'in, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?